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   “ Quale mondo giaccia al di là di  questo mare non so, 
ma ogni mare ha un'altra riva, e arriverò”. 
C. Pavese 
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1. Background and Rationale 
 
1.1  History of Neuroendocrine Tumours 
Neuroendocrine cells were discovered in the 19
th
 century, when the first 
steps for the identification of these cells with peculiar neuronal and secretive 
characteristics were done. At the beginning of the 19
th
 century, Ivan Pavlov 
(1849–1936) and, independently, William Bayliss (1860–1924) and Ernest 
Starling (1866–1927), gave the first empiric demonstrations of the “chemical 
messenger theory” proving the existence of tissue specific substances 
(hormones) able to influence specific organs responses. Starling himself 
recognized that pancreatic gland secretion regulated by both hormones and 
nerves, thus recognising the existence of a gastroenteropancreatic (GEP) 
neuroendocrine system. During the following years many scientists dedicate 
themselves to analyse and characterize the neuroendocrine physiology and 
pathology and in 1867, Theodor Langhans (1839–1915) first described an 
intestinal neoplasm with “unusual appearance”. It was only 40 years later that 
a pathologist, Siegfried Oberndorfer (1876–1944), named these “unusual 
tumours” as “karzinoide”  to differentiate them from true carcinoma. Since 
their identification, several studies have occurred describing the high 
heterogeneity of these tumours in term of both morphology and biology(1).  
 
1.2 Epidemiology of Pancreatic Neuroendocrine Neoplasms 
Neuroendocrine tumours are considered rare neoplasm with an overall 
incidence of 0.2/100.000 person per year(2) although, in the last three 
decades, it was registered a considerably increase of their incidence (Fig 1) 
probably also related to the improvement of clinical and pathological 
diagnostic performance(3). The estimated incidence is expected to reach to 
8/100,000 today with no significant difference between gender. Median age at 
diagnosis is usually 50 years, although they can occur at any age(4).  
Pancreatic neuroendocrine neoplasms (PanNENs) represent the second 
most common epithelial cancer of the pancreas with an incidence of 5% 
among all pancreatic neoplasm(3) and 10-year survival of about 45%(5). 
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1.3 Classification, Staging and Histopathological Diagnosis  
  PanNENs are to date classified according to WHO 2010 classification(5) 
(Fig 2a) which defines three different groups of grading (G) according 
alternatively to the proliferative fraction of neoplastic cells, assessed by 
immunohistochemical evaluation of nuclear stain for ki67, or mitotic count, 
consisting with: pancreatic neuroendocrine tumour low grade (PanNET-G1), 
PanNET-G2 (intermediate grade) and pancreatic neuroendocrine carcinoma 
(PanNEC-G3) (Fig 2a). PanNEC-G3, although rare, are characterized by a 
poorly differentiated morphology and an invariably lethal outcome with a 
mortality of about 100%; conversely the vast majority of pancreatic 
neuroendocrine neoplasms are PanNETs G1 or G2, and despite the well 
differentiated morphology they all possess a malignant potential and an often 
unpredictable clinical behaviour, varying from indolent to highly malignant.  
  Pan-NET G1-G2 are well differentiated neoplasms, characterized by 
various histological architectural patterns (nesting, pseudoglandular, 
trabecular, solid, tubule-acinar) and are composed by well-differentiated 
uniform cells, with a discrete amount of eosinofilic/amphophilic cytoplasm 
and round to oval nuclei, with a characteristic “salt-and-pepper” chromatin 
distribution. Occasionally, rabdoid, clear-cell or oncocytic variants have been 
identified along with  a “pleomorphic” one characterized by large and 
irregular nuclei. The amount of stroma is variable with different grade of 
fibrosis and necrosis is usually very limited or absent. Pan-NETs usually 
express cytokeratins (CK8-18, CK19) and neuroendocrine differentiation 
markers at immunohistochemical analysis (like CD56, Sinaptophysin, 
CromograninA, Neuronal Specific Enolase). Hormone secretion can be also 
demonstrated although functional NETs are defined on the basis of clinical 
symptoms rather than immunohistochemical stains for hormones. Specific 
architectural and morphological pattern are not usually related to specific 
hormones secretion, although in case of insulinoma, amyloid deposits can be 
detected and somatostatin secreting tumours usually show a gland-like 
structures containing psammoma bodies.  
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  Pan-NEC are high grade neoplasms characterized by a large nest or solid 
sheet of poorly differentiated cells (small cell or large cell NEC according to 
size) with scant cytoplasm, irregular nuclei with evident nucleoli. Necrosis 
can be extensive. 
  In recent years the hypothesis of a different pathogenesis among 
PanNETs and PanNECs has been provided by several evidences that 
demonstrated the existence of different molecular alterations between NET 
and NEC(6) and in the next years these findings will probably modify the 
current classifications.  
  Nevertheless, altogether these tumours are staged according to 
TNM/AJCC 7
th
 edition, that include information about size and potential 
infiltration of neighbouring organs and structure (T), nodal status (N) and 
distant metastasis (M) (Fig 2b)(7). An updating of the current classification 
has been proposed by ENETS (European Neuroendocrine Tumours Society) 
(Fig 2b)(8). In the last months the AJCC/UICC classification of PanNENs has 
been updated (8
th
 edition), although it will become effective since 1
st
 January 
2018, thus in the present analysis we referred to the 7
th
 edition. 
 
1.4 Pathogenesis and Molecular Pathology 
PanNETs develop from cells with neuroendocrine characteristics 
belonging to pancreatic islets of Langerhans, although, like the other NETs, 
are an heterogeneous group of neoplasms in term of both clinico-pathological 
characteristics and biological behaviour and their prognostic stratification is 
often challenging(9). 
NETs can occur sporadically or in the setting of clinical syndromes. 
Characteristically PanNETs can be related to multiple endocrine neoplasm 
type 1 (MEN1) syndrome in 10-20% of cases, although several syndromes 
have been described to be associated with the occurrence of PanNETs 
(namely von Hippel-Lindau disease and less commonly neurofibromatosis 
type 1, tuberous sclerosis complex and in families with germline mutations in 
cyclin-dependent kinase inhibitor genes)(10).  
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Genes involved in the abovementioned syndromes can also act as drivers 
in sporadic PanNETs tumorigenesis. Lessons from the analysis of these 
familial syndromes along with reports on genetic and epigenetic alterations of 
non-familial NETs, have increased our understanding of mutational 
mechanisms that entail the pathogenesis of neuroendocrine tumours.  
MEN1 gene, located on chromosome 11q13 and encoding for menin, was 
found to be altered by inactivating mutations coupled with loss of 
heterozigosity of the wild-type allele(11), in about 35% of cases of 
PanNETs(12). Furthermore in a recent study on 169 PanNETs, Corbo et al, 
reported an altered menin expression in 80% of cases while known molecular 
alteration of MEN1 were identified at low frequency (in 35% of cases) only 
partly explaining the higher rate of protein dysfunction(13).  
Along with MEN1 mutations, inactivating mutation in DAXX (death-
domain-associated protein) and ATRX (alpha thalassemia/mental retardation 
syndrome X-linked) have been described in about 43% of PanNETs, as well 
as activating mutations in the PI3K-AKT-mTOR pathway(12). Less frequent 
mutations have been detected in ATM (5.5%) and KIT (2.7%)(14) and VHL 
and PTEN(15) while no mutations have been identified in genes commonly 
mutated in pancreatic ductal adenocarcinoma (i.e. KRAS, TP53, CDKN2A 
and SMAD4)(16).  
DAXX and ATRX belong to the chromatin remodeling pathway and 
mutually exclusive mutations have been reported in about 40% of sporadic, 
variably associated with MEN1 mutations(12, 17). DAXX and ATX mutation 
are correlated with alternative telomerase independent telomere maintenance 
mechanism named alternative lengthening of telomeres (ALT)(18). 
DAXX/ATRX mutation and ALT have been identified in PanNETs and not in 
neuroendocrine micro adenomas; furthermore these abnormalities have been 
observed in higher grade (G2 versus G1) and larger sized cases (tumor 
diameter >3 cm)(19) along with reduced survival(20), suggesting the late 
occurrence of these alterations in PanNETs tumorigenesis. 
MTOR-pathway deregulation is also considered another important 
pathogenic mechanism in PanNETs, determining an important stimuli to cell 
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survival, cell proliferation, metabolism and angiogenesis; this pathway 
encompass several genes that have been described to be potentially altered in 
PanNETs (like PTEN, AKT, PI3KCA, MEN1, VHL, NF1, TSC1 and TSC2, 
several tyrosine kinases receptors)(10). Furthermore numerous reports have 
highlighted the role of m-TOR pathway activation as poor prognostic 
indicator in PanNETs(21-23). Although the mTOR inhibitor Everolimus is 
FDA approved for the treatment of advanced PanNET(24), selection of 
patients who will benefit of this therapy based on molecular analysis is yet to 
be developed. 
Copy number analysis identified several chromosomal aberrations 
common in PanNETs, mainly loss of chromosome 11q(containing the genes 
MEN1, BRCA2 and ATM), 11p and 6q,  as well as gains in 17q 
(NEU/ERB2), 7q and 20q (AURKA, cMET) along with LOH at specific 
chromosomal loci (PTEN, MEN1 and PHLDA3)(10). 
 
1.5 Rationale 
  Despite the great advantages in the knowledge of molecular alterations 
that unveil pathogenic mechanism along with some prognostic and predictive 
factors, our current understanding of the molecular pathology of PanNETs, is 
insufficient for an appropriate clinical management, where the most important 
clinical challenge is to predict the aggressiveness of individual tumours in 
order to select patients for the more appropriate therapy differentiating who 
will benefit from early aggressive therapy from those patients with indolent 
disease that conversely would be exposed to inadvertent overtreatment.   
  Here, a comprehensive molecular analysis of 102 clinically sporadic 
PanNETs belonging from a multi-centric cooperative group (ARC-Net 
Research Centre at Verona University, Australian Pancreatic Cancer Genome 
Initiative -APGI, and Baylor College of Medicine as part of the ICGC, 
www.icgc.org) defines their molecular pathology and identifies several 
candidate novel mechanisms that activate mTOR signalling including novel 
gene fusion events. We uncover an important role for germline MUTYH 
variants through a novel G:C>T:A mutational signature. Moreover, we 
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identify a larger than anticipated germline contribution to clinically sporadic 
PanNET, delineating future challenges in the clinical assessment of 
susceptibility. 
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2 Results and Discussion 
 
2.1 Cohort Characteristics 
Patients were recruited and consent for genomic sequencing obtained as 
part of the International Cancer Genome Consortium (www.icgc.org). All 
cases were classified according to WHO criteria updated to ENETs 
classifications(5, 8).  
The discovery cohort included 98 resected PanNETs (Table 1) with an 
average tumour content of 82%(25);  36 cases were classified as G1, 57 as 
G2, and 5 as G3. Additional 62 cases of PanNETs and one colon cancer from 
a MUTYH associated Polyposis (MAP)  were included in the study as 
validation cohort, of which 4 PanNETs and the CRC underwent whole 
genome sequencing to validate mutational signatures (data not shown), while 
all the 62 PanNETs were also analysed by targeted next-generation 
sequencing and FISH to validate somatic/germline variants and fusion 
transcript respectively. 
 
2.3 Study design  
The analyses were conducted on a discovery cohort of 98 PanNETs and on 
a validation set of an additional 62 PanNETs and 1 colorectal cancer.  
The discovery cohort underwent whole genome sequencing (WGS) for the 
examination of telomere length, structural variants, somatic/germline variants 
and mutational signature analysis. C-tailing qPCR was performed on 86 cases 
of the discovery set in order to validate WGS-telomere length analysis and to 
detect the presence of alternative telomere lengthening (ALT) mechanism. 
SNP array analysis was performed on the whole discovery cohort in order to 
detect copy number variation. 
The presence of specific chromosomal structural variants detected by 
WGS were validated by RNAseq. Fluorescent in situ hybridization (FISH) 
using a break-apart probe, was used to demonstrate the presence of EWSR1 
rearrangements in 4 cases (3 from discovery and 1 from validation PanNETs 
cohort). Finally to validate the presence of fusion transcript related to EWSR1 
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rearrangement, RT-PCR analysis was performed, followed by Sanger 
sequencing of the detected products. 
Amplicon sequencing was performed on the 62 cases of validation set to 
confirm the WGS data on somatic variants and MUTYH mutational signature. 
Four PanNETs of validation cohort and the colorectal cancer case underwent 
WGS to validate mutational signature data and germline/somatic variants 
detected by WGS. 
 
2.3 Mutational mechanisms 
PanNETs are characterized by a lower mutation burden (0.82 per 
megabase, range 0.04-4.56) compared with their exocrine counterpart(26) 
(pancreatic ductal adenocarcinoma: mean 2.64, range 0.65–28.2), with the 98 
PanNETs containing 258,678 high confidence somatic point mutations and 
indels.  
Non-negative Matrix Factorization(27) defined 5 robust mutational 
signatures (Fig. 3a) consisting with: the unknown aetiology ‘Sanger signature 
5’(27) reported in many tumour types, Deamination signature, AID/APOBEC 
signature, BRCA signature and a previously “undescribed” signature, named 
“novel signature”. The germline heterozygous APOBEC3A-3B deletion 
identified in 13 cases resulted prevalent only in 2 PanNETs indicating that 
this signature, implicated in APOBEC-induced mutation(s) in breast 
cancers(28), plays a minor role in PanNETs (Fig. 3a). Only one case 
harbouring a pathogenic germline BRCA2 mutation (Fig. 3c) carried a highly 
prominent BRCA-deficiency signature (>2mutations/Mb), with high genomic 
instability similarly to what previously described in BRCA-deficient 
breast(29), pancreatic ductal(26), ovarian(30) and oesophageal 
carcinomas(31). The novel mutational signature, composed of G:C>T:A 
transversions, resulted predominant in 5 PanNETs (range 0.2-4.2 
mutations/Mb) (Fig. 3a),. bearing a known pathogenic or novel-damaging 
germline mutation in the Base-Excision-Repair gene MUTYH, coupled with 
LOH (Fig. 3d). This pattern of biallelic MUTYH inactivation was not 
observed in 100 pancreatic ductal adenocarcinomas using the same analysis 
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pipeline(26). Germline biallelic inactivation of MUTYH  is involved in the 
pathogenesis of colorectal MUTYH associated polyposis (MAP), an autosomal 
recessive syndrome associated with somatic G:C>T:A transversions in the 
APC gene, the driver of colorectal polyps(32). To verify our findings, 
amplicon sequencing of MUTYH on 62 additional PanNETs identified 3 
tumours bearing pathogenic germline mutations coupled with LOH. Whole 
genome analysis revealed that these three tumours displayed the same novel 
mutational signature (Fig. 3b). Interestingly, the two missense MUTYH 
mutations identified in the Italian cohort (c.527A>G, p.Y176C; c.1178G>A, 
p.G393D) are the most common MAP-linked variants in populations of 
European origin and have been shown to be founder mutations in a recent 
haplotype analysis of 80 MAP families from Italy and Germany(33). Finally, 
WGS of a colonic tumour from a MUTYH associated polyposis patient 
confirmed that this signature indicates MUTYH deficiency (Fig. 3b). These 
data suggest that, in addition to predisposing to colonic, gastric and a variety 
of non-gastrointestinal cancers(34), MUTYH deficiency plays a role in 
PanNETs.  
Chromothripsis defined by the accumulation of thousands of clustered 
chromosomal rearrangements in a single event and in localised and confined 
genomic regions or in one or a few chromosomes (35), was detected in  9 
tumours (9%), consisting with the presence of clusters of breakpoints (Fig. 4). 
All those cases displayed structural variations and copy-number changes (data 
not shown) and  interestingly, 4 out of 9 tumours had recurrent catastrophic 
rearrangements on chromosome 11q (Fig. 4b), all involving 11q13, and 2 led 
to loss of MEN1. Notably, despite TP53 being considered a hallmark of 
chromothripsis(36), no TP53 mutations were present in tumours with genomic 
catastrophes in PanNETs. 
 
2.4 Germline Mutations 
The discovery of germline deleterious mutations of MUTYH and BRCA2 
prompted us to screen the germline of all patients for mutations in DNA 
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damage repair genes or genes associated with hereditary syndromes (data not 
shown).  
In the case of known neuroendocrine predisposition genes, 6 patients 
carried either known pathogenic or novel deleterious germline MEN1 
mutations (4 frameshifts, 1 splice site-mutation, and 1 copy-number loss).  
A single novel truncating CDKN1B germline mutation was identified 
(Q163X). CDKN1B germline mutations cause Multiple Endocrine Neoplasia 
Type 4(37) and its somatic mutations have been recently described in small-
intestinal NET(38). In addition a single, novel, pathogenic germline mutation 
was identified within VHL, a negative regulator of hypoxia signalling known 
to promote neuroendocrine proliferation and PanNETs development(39). 
Germline alterations were coupled with somatic LOH in all cases.  
CHEK2, belonging to DNA-damage repair pathway and a known tumour 
suppressor in breast and other cancer types, had predicted damaging germline 
variants in 4 cases (4%): a nonsense mutation (c.58C>T, Q20X), a 15bp in 
frame deletion (c.246-260del, p.D77-E82del), a missense mutation in exon 2 
implicated in prostate cancer predisposition (rs121908702, c.844G>A, 
p.E282K)(40) and a missense variant in exon 4 (c.529G>C, p.D177H). 
Mutation modelling predicted these variants to be damaging.  
 
2.5 Somatic driver mutations 
A total of 15,751 somatic coding mutations of which 7,703 non-silent, 
were detected in 2,787 genes (data not shown). Sixteen significant, 
recurrently-mutated genes were defined using IntOGen(41) analysis (Q-value 
<0.1) (Fig. 5a).  
As previously reported, MEN1 was the most frequent mutated genes in 
37% of tumours (Fig. 5b). Mutually exclusive inactivating mutations of 
DAXX and ATRX were found in 22 and 11 samples, including a structural 
rearrangement of ATRX, respectively.  
Members of the mTOR pathway PTEN (n=7) and DEPDC5 (n=2) were 
also significantly mutated. PTEN mutations were mutually exclusive to TSC1 
(n=2) and TSC2 (n=2), other negative regulators of mTOR signalling (Fig. 
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5a). Mutations of the tumour suppressor gene DEPDC5 have not been 
previously described in PanNETs; hence we surveyed additional 62 PanNETs 
cases (data not shown) and identified additional 2 tumours harbouring 
DEPDC5 mutations, which resulted to be again mutually exclusive to PTEN 
(n=3) and TSC2 (n=3) also in this validation set (data not shown).  
Consistent with literature data, deleterious TP53 mutations were 
uncommon (n=3). Among the genes not meeting the significance threshold by 
IntOGen, SETD2, an histone modifier, resulted mutated in 5 samples (Fig. 
5a). Multiple independent SETD2 mutations were observed in presumed sub-
clones of one tumour (a nonsense at 3%, a missense at 14% and a frameshift 
at 11% allelic frequency), suggesting strong selection for SETD2 inactivation 
in that particular tumour, similarly to previous observations in renal cell 
carcinoma(42). 
 
2.6 Copy number changes  
Copy number analysis revealed the presence of 4 discrete groups based on 
arm length copy number patterns (Fig. 6). These were classified into: 1) 
recurrent pattern of whole chromosomal loss (RPCL); 2) limited copy number 
events, many of which were losses affecting chromosome 11; 3) polyploid; 
and 4) aneuploid (Fig. 6a and b). Interestingly, the RPCL subtype consistently 
presented loss of specific chromosomes (Fig. 6) and was significantly 
enriched in G2 PanNETs (P=0.0247, Chi-square test). The polyploid group 
had the highest somatic mutation rate (P≤0.002, Mann-Whitney test) with an 
average of 1.98 mutations/Mb (Fig. 6c).  
Recurrent regions of gain and loss (Fig. 6d) included broad regions of loss 
containing known neuroendocrine tumour suppressors MEN1 (chromosome 
11q13.1) and CDKN2A (chromosome 9q21.3), while focal losses highlighted 
potential tumour suppressor roles for EYA1 (chromosome 8q13.3) a known 
target of MEN1(43), SFMBT1 (chromosome 3p21.1) a key component of 
histone modification machinery implicated in cancer(44), and RABGAP1L 
(chromosome 1q25.1), a gene frequently deleted in neurofibromas(45). 
Significant, recurrently-amplified regions included: PSPN (chromosome 
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19p13.3), a member of the glial cell line-derived neurotrophic factor family, 
known to activate PIK3CA-signalling via RET and upregulated in thyroid 
medullary cancers(46, 47); and ULK1 (chromosome 12q24.33), a serine-
threonine kinase that is involved in mTOR regulated autophagy(48). 
 
2.7 Chromosomal rearrangements 
Structural rearrangements are less common in PanNETs (mean, 29 events 
per tumour; range 3–216) (data not shown) compared to pancreatic ductal 
adenocarcinoma (119 per tumour; range 15–558)(26). Inactivation of tumour 
suppressor genes through rearrangement occurred in MTAP (n=4), ARID2 
(n=5), SMARCA4 (n=3), MLL3 (n=3), CDKN2A (n=1), and SETD2 (n=1).  
Rearrangements can also generate oncogenic drivers through in-frame 
gene fusions. 66 somatic fusions capable of expressing in-frame chimeric 
genes were identified (data not shown). Interestingly, EWSR1 gene was 
involved in fusion events in 3 PanNETs. Two tumours possessed in-frame 
EWSR1-BEND2 fusion genes, which were expressed as mRNA (Fig. 7a and 
b), defining BEND2 as a novel EWSR1 fusion partner. Noteworthy, BEND2 
was recently reported as a fusion partner of MN1, encoding for a 
transcriptional activator involved in meningioma development, in CNS high-
grade neuroepithelial tumour(49). One tumour contained an EWSR1 exon 7 - 
FLI1 exon 6 gene fusion confirmed by RNAseq (Fig. 7c). EWSR1-FLI1 
fusions occur characteristically in Ewing’s sarcomas(50, 51) although has 
been recently reported in other cancers(52) and rarely in pancreas or 
gastrointestinal tract(53). The 3 fusion events involved the region of EWSR1 
that is most susceptible to breakage/translocation in a variety of soft tissue 
tumours and Ewing sarcoma, and can be detected by fluorescent in situ 
hybridization (FISH) analysis using break-apart probes for EWSR1 (Fig. 7a-
c). By applying FISH on the 62 cases of the validation cohort, we identified 
an additional PanNET with positive split signals due to an EWSR1 exon 7 - 
FLI1 exons 5 fusion (Type II) confirmed at the mRNA level (Fig. 7d). Ewing 
sarcoma is a distinctive poorly differentiated high grade round cell sarcoma 
that most often (but not exclusively) affect children and young adults (< 25 
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years); they characteristically develop in soft tissue and bone and are 
exceedingly rare in other sites. Ewing tumours, typically show a strong 
membranous expression of membrane glycoprotein CD99(54) and specific 
inactivation of tumour suppressor genes (STAG2, TP53 and CDKN2A) or 
chromosomal copy-number variations (gains of chromosome 8 and 1q)(55-
57). Conversely the 4 PanNETs cases bearing EWSR1 fusions had 
morphological and immunophenotypical features typical of PanNET (i.e. 
strong immunoreactivity for chromogranin and synaptophysin), with absent to 
faint staining for CD99, lack Ewing’s sarcoma typical molecular alterations 
while showed characteristic PanNETs mutations (in MEN1, ATRX and TSC2). 
Nonetheless, the 3 cases of the discovery cohort resulted metastatic at 
diagnosis with a relatively short survival for PanNETs (25 months for #0993, 
51.5 months for #0152, and 7 months for #0457), suggesting that those 
fusions possibly identify more aggressive subtypes of PanNETs. Furthermore 
the result of CD99 immunohistochemical analysis on a subset of discovery 
cohort cases (54 PanNETs) and on the validation cohort, showed that 35 
(30%) cases immunostained for CD99, 18 (15%) of which had a very strong 
signal; however, none of these cases had FISH split signals related to EWSR1 
rearrangement. CD99 is generally used to guide diagnosis of Ewing sarcoma. 
Our data, along with further literature reports, highlight expression of this 
antigen in a significant fraction of neuroendocrine tumours of different 
anatomical sites(58, 59) with important implication for histopathological 
differential diagnosis.  
 
2.8 Telomere integrity and PanNET molecular subtypes  
Telomere repeat content was quantified using WGS data, and ALT 
assessed by C-Tailing qPCR in 86 cases. 22 out of 26 ATRX/DAXX mutant 
tumours displayed ALT, and more frequent in DAXX (19/22) than ATRX 
(3/22) mutants, in contrast to in vitro studies where ATRX alterations are more 
prevalent(60). Biallelic inactivation of ATRX/DAXX through LOH was 
strongly associated with an increase in telomere length (P<0.0001, Mann-
Whitney test) (data not shown). MEN1 somatic mutations were also 
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associated with increased telomere length (P<0.0001, Mann-Whitney test) 
(data not shown), suggesting a role for MEN1 in chromosome maintenance. 
To better understand the consequences of ALT, somatic telomere content 
was compared to copy-number and structural variation patterns (Fig. 8). The 
presence of short telomeres was associated with genomic catastrophes and 
EWSR1 fusions, consistent with observations that telomere exhaustion plays a 
role in chromothripsis and bridge-fusion-break events in solid cancers. 
Interestingly, tumours with ALT were strongly associated with the PanNET-
RPCL phenotype, with 16/21 tumours with RPCL displaying ALT. Tumours 
with ALT, have been previously reported to undergo copy gain and loss in 
recurrent regions of genes in a panel of human cancer cell lines in vitro(60), 
differently from PanNETs where whole loss of specific chromosomes 
predominates. 
 
2.9 Integrated analysis of PanNET cancer pathways  
Four pathways were commonly altered by mutations in PanNETs whose 
perturbations may define potentially clinically relevant subtypes for a more 
accurate stratification of therapeutic approaches (Fig. 4): 
i) DNA damage repair: Germline damaging variants of the base-excision-
repair MUTYH gene, and homologous recombination genes CHEK2 and 
BRCA2 were present in 11% of patients.  
ii) Chromatin remodelling: MEN1, SETD2, ARID1A and MLL3 were 
recurrently inactivated, and likely drive widespread transcriptional 
dysregulation.  
iii) Telomere Maintenance: Upregulation of TERT and telomere lengthening 
is a well-established pro-survival mechanism in solid tumours. MEN1 binds 
the TERT promoter and influences the machinery controlling telomere 
integrity(61). Consistent with previous reports, inactivating mutations in 
DAXX or ATRX were present in one third of PanNETs and correlated strongly 
with somatic telomere repeat content and telomere length (Extended Data 8b 
and c). Tumours harbouring DAXX/ATRX mutations were associated with a 
poor prognosis in the G2 subgroup, and correlated significantly with 
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mutations in mTOR regulators (Fig. 9a and b, Table 2). Tumours with 
unaltered telomere length had a better outcome (Extended Data 10c).  
iv) mTOR signalling activation: The role of mTOR in PanNETs is well 
established(12, 23). Inactivating mutations in negative regulators of mTOR 
signalling (PTEN, TSC2, and herein reported TSC1 and DEPDC5) were 
present in 12% of patients, and were associated with a poor prognosis in the 
G2 subgroup of patients (HR=6.85, 95%CI=1.14 – 41.7; P= 0.0353, Fig. 9d, 
Table 1). These may represent putative biomarkers for patient selection for 
mTOR inhibitor therapy(24). We uncovered 3 potential novel mTOR pathway 
activation mechanisms: a) inactivating mutations of tumour suppressor 
DEPDC5, encoding a subunit of the GATOR1 complex, a suppressor of 
mTOR signalling(62), b) a putative mTOR activation mechanism involving 
EWSR1 fusion genes, and c) amplification of the RET receptor ligand PSPN.  
Moreover, inactivation of MEN1, that has a broad range of functions, 
directly impacts on all these 4 key processes(61, 63-65) (Fig. 10). MEN1 
encodes the histone modifier Menin and its inactivation drives a variety of 
phenotypes including widespread transcriptional dysregulation via histone 
modification(65), activation of mTOR through AKT expression(64), 
suppression of homologous recombination DNA damage response genes(63) 
and dysregulation of TERT(61). 
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        3.      Conclusion 
With the present analysis we describe the mutational landscape of 
PanNETs and mutational signatures underlying their pathogenesis, including a 
novel mutational mechanism due to MUTYH inactivation. We uncover novel 
mTOR pathway activation mechanisms including DEPDC5 inactivation and 
EWSR1 fusion events In addition, we identify PanNET subtypes based on 
global copy number profiles and gene mutations that have potential clinical 
utility. There are 3 major clinical considerations that have to be done:  i) 
DAXX/ATRX and mTOR pathway genes mutational status may serve as novel 
biomarker for prognostic stratification of intermediate grade PanNETs (G2), 
the subgroup that represent the most challenging one with the least predictable 
clinical behaviour. This calls for exploration of its clinical utility in 
prospective clinical trials.  ii) The identification of novel mechanisms that 
activate mTOR signalling may represent selection biomarkers of therapeutic 
responsiveness to mTOR inhibitors such as Everolimus, which are currently 
poorly defined. iii) The discovery of a larger than aspected germline mutation 
contribution to PanNET development, particularly in patients without a family 
history, has implications for clinical management  for individuals that carry 
these mutations and have an increased, yet unquantifiable risk of disease.   
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4. Figures and Tables  
 
Fig.1  
 
Fig.1 |  Incidence of NETs in the past 3 decades. An exceptional increase 
in NETs incidence have been recorded in the last 30 years. The improvement 
of clinico-pathological diagnostic tools can partly explain this drastic 
increment of NETs cases (from SEER Survival Monograph).  
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Fig. 2 
 
 
 
Fig. 2 | Grading and Staging of PanNETs. a. Grading of PanNETs 
according to WHO 2016. b. Comparison between AJCC/TNM staging system 
and ENETs-modified proposal for TNM.  
  
<2 
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Fig. 3 
 
 
 
Fig. 3 | Mutational signatures in pancreatic neuroendocrine tumours. a 
Five signatures (A-E) were identified in 98 PanNET samples. Signature A is 
novel and has been named MUTYH because all tumours dominated by this 
signature carried a germline inactivating mutation in MUTYH with concurrent 
loss of the wild-type allele; signatures B to E have been previously described 
and are reported with their given names. Tumours with a high MUTYH, 
APOBEC, BRCA or Age signature showed a higher number of mutations per 
Mb. b Validation of MUTYH signature in 4 additional PanNETs and 1 colon 
tumour. Three PanNET and the colon tumour contained a dominant MUTYH 
signature and harboured a germline damaging MUTYH mutation with 
concurrent loss of the wild-type allele, while a PanNET with a benign 
MUTYH variant did not contain the signature. c The tumour with the BRCA 
signature contained a BRCA2 germline variant (R3052W) and genomic 
instability as seen in pancreatic ductal adenocarcinoma. d Variants displayed 
above the MUTYH protein were associated with the MUTYH signature and 
contained somatic biallelic inactivation of the MUTYH gene (highlighted in 
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bold), those below were not and are either benign or showed no loss of the 
wild-type allele. Variants reported by Clinvar as pathogenic (#) are shown. 
Variants predicted by SIFT as deleterious and Polyphen as probably 
damaging are underlined. All mutations shown are for the transcript 
ENST00000372098.3 and protein ENSP00000361170.3. 
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Fig. 4 
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Fig. 4 | Structural rearrangements in pancreatic neuroendocrine 
tumours. a Upper panel: the number and type of somatic structural 
rearrangements in each tumour. Lower panel: tumours with more events 
tended to have longer telomeres. b Two methods were used to determine 
clusters of somatic structural rearrangement breakpoints. Orange squares: 
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chromosomes with a significant cluster of events as determined by a goodness 
of fit test against the expected distribution (p<0.0001, Kolmogorov–Smirnov 
test). Blue squares: chromosomes deemed to harbour a high number of 
breakpoints because they had a chromosomal breakpoint per Mb rate which 
exceeded the 75th percentile of the chromosomal breakpoint/Mb rate for the 
cohort by 5 times the interquartile range. Red squares: chromosomes where 
both these criteria were met. Clusters of events were reviewed and 9 tumours 
were found to harbour regions of chromothripsis. c Recurrent chromothripsis 
for chromosome 11 was detected in 4 tumours. The chromothripsis event 
caused loss of the MEN1 gene locus in 2 of these samples. 
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Fig. 5 
 
 
 
Fig. 5 | Recurrently mutated genes in pancreatic neuroendocrine 
tumours.  a The number of SNVs and indels within the genome of each 
patient (n=98) is shown in the histogram. The driver plot displays the somatic 
mutations in key genes or those identified as significantly mutated (Intogen 
31 
 
Q-value <0.1). SETD2 is also reported, although its Q-value was 0.15, as it 
was recurrently inactivated in 6 samples and multiple independent deleterious 
SETD2 mutations were observed in one tumour (a nonsense present at 3%, a 
missense at 14%, and a frameshift at 11 %, only the nonsense is shown but the 
case is highlighted with a black arrow), suggesting strong selection for SETD2 
inactivation in that tumour. b Somatic mutations in MEN1 are predominantly 
nonsense mutations or insertions-deletions causing frame shift and premature 
protein termination, and occur throughout the protein.  
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Fig. 6 
 
          
 
Fig. 6 | Genome characteristics of pancreatic neuroendocrine tumours. 
Copy number was determined using Illumina SNP arrays in a cohort of 98 
PanNETs. a Copy number events were mainly comprised of whole 
chromosome arm loss or gain. Cluster analysis of the chromosome arm level 
copy number state stratified the tumours into 4 subtypes: Group 1: recurrent 
pattern of whole chromosomal loss, affecting specific chromosomes (1, 2, 3, 
6, 8, 10, 11, 15, 16 and 22); Group 2: samples with limited number of events, 
many of which with loss affecting chromosome 11; Group 3: polyploid 
tumours, with gain of all chromosomes; and Group 4: aneuploid tumours, 
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containing predominantly whole chromosome gains affecting multiple 
chromosomes). b The proportion of bases within the genome affected by copy 
number change. c The mutations per Megabase (SNPs and small insertion 
deletions) and  d GISTIC analysis showing recurrent gains (red) and losses 
(blue) of the entire cohort.  
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Fig. 7 
 
 
 
Fig. 7 | EWSR1 gene fusions in pancreatic neuroendocrine tumours. a and 
b Somatic fusion events between EWSR1 and BEND2 confirmed in RNA by 
capillary electrophoresis of RT-PCR products. Representative sections 
showing typical PanNET morphology (H&E) and immunoreactivity for the 
neuroendocrine marker Chromogranin A (inset), lack of immunostaining for 
CD99, and positive EWSR1 split signals (arrowheads) detected with 
fluorescent in situ hybridization (FISH). c Somatic fusion event between 
EWSR1 and FLI1 confirmed by RNAseq. Representative sections showing 
typical PanNET morphology (H&E) and immunoreactivity for Chromogranin 
A (inset), faint immunoreactivity for CD99, and positive EWSR1 split signals 
(arrowheads) at FISH. d Somatic fusion event between EWSR1 and FLI1 
confirmed by capillary electrophoresis of RT-PCR products. Representative 
sections showing typical PanNET morphology (H&E) and immunoreactivity 
for Chromogranin A (inset), strong immunoreactivity for CD99, and positive 
EWSR1 split signals (arrowheads). Scale bar represents 100µm. Insets, 600x 
magnification. 
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Fig. 8 
 
 
 
Fig. 8 | Mutational processes in pancreatic neuroendocrine tumours. a 
Telomere length was estimated using whole genome sequencing in a cohort of 
98 PanNETs. The relative telomere length in each tumour compared to the 
matched normal is shown as log2. A total of 24 tumours contained telomeres 
which were 1.5x longer than matched normal DNA and 36 contained 
telomeres which were 1.5x shorter compared to matched normal DNA. b 
Most of the tumours with long telomeres had ALT and 13 of the tumours 
contained genomes with large amounts of whole chromosome arm losses. 
Somatic mutations in DAXX/ATRX were strongly associated with an increase 
telomere length (p<0.0001, Mann-Whitney test). Tumours with short 
telomeres contained fewer mutations in DAXX/ATRX and more 
chromothripsis events or EWSR1 gene fusions.  
  
36 
 
Fig. 9 
 
 
Fig. 9 | Genomic events associated with outcome. Kaplan-Meier survival 
curves demonstrating: a tumours harbouring DAXX/ATRX mutations had a 
poor prognosis in the whole cohort and b in the G2 cohort. c tumours with 
telomere length that are neither short or long had a better prognosis, and d 
tumours harbouring mutations in genes that activate mTOR pathway had a 
poor prognosis in the G2 cohort (Chi-squared test was used in all instances). 
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Fig. 10 
 
 
Fig. 10 | Core pathways in pancreatic neuroendocrine tumours. The 
frequency of somatic mutations and copy number change are shown in key 
genes of the mTOR signalling pathway, histone modification, altered telomere 
length and DNA damage repair pathways. MEN1, which is frequently mutated 
in pancreatic neuroendocrine tumours is involved in all these processes. 
Activating changes (red) include copy number change of 6 or more and 
inactivating changes (blue) include copy number 1 or copy number two with 
LOH. Genes that also contain germline variants predicted as pathogenic are 
shown (^). ATRX is located on chromosome X and showed point mutations in 
6 males and 4 females, and in three of the females the inactivation was 
biallelic by LOH (*). 
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Table 1 
Summary of clinicopathological variable and outcome analysis for 98 pancreatic 
neuroendocrine tumours patients. 
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Table 1 (continues) 
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Table 2 
Summary of DAXX/ATRX mutational status correlation to clinico-pathological 
variables. 
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5. Methods 
5.1 Human research ethical approval  
   ARC-Net, University of Verona: approval number 1885 from the Integrated 
University Hospital Trust (AOUI) Ethics Committee (Comitato Etico Azienda 
Ospedaliera Universitaria Integrata) approved in their meeting of 17 
November 2010 and documented by the ethics committee 52070/CE on 22 
November 2010 and formalized by the Health Director of the AOUI on the 
order of the General Manager with protocol 52438 on 23 November 2010. 
APGI: Sydney South West Area Health Service Human Research Ethics 
Committee, western zone (protocol number 2006/54); Sydney Local Health 
District Human Research Ethics Committee (X11-0220); Northern Sydney 
Central Coast Health Harbour Human Research Ethics Committee (0612-
251M); Royal Adelaide Hospital Human Research Ethics Committee 
(091107a); Metro South Human Research Ethics Committee (09/QPAH/220); 
South Metropolitan Area Health Service Human Research Ethics Committee 
(09/324); Southern Adelaide Health Service/Flinders University Human 
Research Ethics Committee (167/10); Sydney West Area Health Service 
Human Research Ethics Committee (Westmead campus) (HREC2002/3/4.19); 
The University of Queensland Medical Research Ethics Committee 
(2009000745); Greenslopes Private Hospital Ethics Committee (09/34); North 
Shore Private Hospital Ethics Committee. Baylor College of Medicine: 
Institutional Review Board protocol numbers H-29198 (Baylor College of 
Medicine tissue resource), H-21332 (Genomes and Genetics at the BCM-
HGSC), and H-32711(Cancer Specimen Biobanking and Genomics ). 
 
5.2 PanNET Patient and Tissue Cohort 
Patients were recruited and consent obtained for genomic sequencing 
through the ARC-Net Research Centre at Verona University, Australian 
Pancreatic Cancer Genome Initiative (APGI), and Baylor College of Medicine 
as part of the ICGC (www.icgc.org). A patient criterion for admission to the 
study was that they were clinically sporadic. This information was acquired 
through direct interviews with participants and a questionnaire regarding their 
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personal history and that of relatives with regard to pancreas cancers and any 
other cancers during anamnesis. Investigations were also done on clinical 
records to clarify familial history based on the patient indication.  
Samples were prospectively and consecutively acquired through 
institutions affiliated with the Australian Pancreatic Cancer Genome 
Initiative. Samples from the ARC-Net biobank are the result of a consecutive 
collection from a single centre. 
All tissue samples were processed as previously described(66). 
Representative sections were reviewed independently by at least one 
additional pathologist with specific expertise in pancreatic diseases. Samples 
either had full face frozen sectioning performed in optimal cutting 
temperature (OCT) medium, or the ends excised and processed in formalin to 
verify the presence of tumour in the sample to be sequenced and to estimate 
the percentage of neoplastic cells in the sample relative to stromal cells. 
Macrodissection was performed if required to excise areas that did not contain 
neoplastic epithelium. Tumour cellularity was determined using SNP arrays 
(Illumina, San Diego) and the qpure tool(25).  
 
5.3 Sample size 
PanNET is rare tumour type and the samples have been collected via an 
International Network. We estimate that with 98 unique patients in the 
discovery cohort, we will achieve 90% power for 90% of genes to detect 
mutations that occur at a frequency of ~10% above the background rate for 
PanNET (assuming a somatic mutation frequency of  < 2 per Mb)(67). 
 
5.4 Colon sample acquisition  
Cancer and matched normal colonic mucosa were collected at the time of 
surgical resection from the Royal Brisbane and Women’s Hospital and snap 
frozen in liquid nitrogen. A biallelic germline mutation in the MUTYH gene 
was detected by restriction fragment length polymorphism analysis and 
confirmed by automated sequencing to be the G382D mutation (or 
ENST00000372098 G393D) in both alleles(68).  
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5.5 Immunohistochemistry 
The primary antibodies used for immunohistochemical staining were: 
Cytokeratin 8/18 (5D3, Novocastra), Chromogranin A (DAK-A3, Dako), and 
CD99 (O13, Biolegend). Antibodies and staining conditions have been 
described elsewhere(53). 
 
5.6 Sequencing and mutation analysis 
Matched tumour/normal DNAs underwent whole genome sequencing 
(WGS) (average 38x normal/61x tumour) and high-density SNP arrays (data 
not shown), and orthogonal testing estimated the accuracy of somatic calls to 
exceed 99%. Whole genome sequencing with 100bp paired reads was 
performed with a HiSEQ2000 (Illumina, San Diego). Sequence data was 
mapped to a GRCh37 using BWA and BAM files are available in the EGA 
(Accession number: EGAS00001001732). Somatic mutations and germline 
variants were detected using a previously described consensus mutation 
calling strategy(30). Mutations were annotated with gene consequence using 
SNPeff. The pathogenicity of germline variants was predicted using cancer-
specific and locus-specific genetic databases, medical literature, 
computational predictions with ENSEMBL Variant Effect Predictor (VEP) 
annotation, and second hits identified in the tumour genome. Intogen(41) was 
used to find somatic genes which were significantly mutated. Structural 
rearrangements were detected by integrating discordant read pairs, soft-
clipping, split read & de novo assembly of non-mapping reads using the qSV 
tool as previously described(30, 31). Coding mutations are included in 
supplementary tables (data not shown) and all mutations have been uploaded 
to the ICGC DCC. 
 
5.7 Mutational signature  
Mutational signatures were predicted using a published framework(27). 
Essentially the 96 substitution classification was determined for each sample. 
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The signatures were compared to other validated signatures and the 
prevalence of each signature per Mb was determined.  
 
5.8 Copy number analysis 
Somatic copy number was estimated using high density SNP arrays and 
the GAP tool(69). Arm level copy number data was clustered using Ward’s 
method, Euclidian distance. GISTIC(70) was used to identify recurrent 
regions of copy number change. 
 
5.9 Telomere length  
The whole genome sequence data was used to determine the length of the 
telomeres in each sample using the qMotif tool. Essentially, qMotif 
determines telomeric DNA content by calculating the number of reads which 
harbour the telomere motif (TTAGG), and then estimates the relative length 
of telomeres in the tumour compared to the normal. qMotif is available online 
(http://sourceforge.net/projects/adamajava). Telomere length was validated by 
qPCR as previously described(71). 
 
5.10 Validation of fusion transcripts 
Two different strategies were used to verify fusion transcripts. For 
verification of EWSR1-BEND2 fusions, cDNAs were synthesized by using the 
SuperScript VILO cDNA synthesis kit (Thermofisher) with 1µg of purified 
total RNA. For each fusion sequence three samples were used: the PanNET 
sample containing the fusion, the PanNET sample without that fusion, and a 
non-neoplastic pancreatic sample. The RT-PCR product were evaluated on 
the Agilent 2100 Bioanalyzer (Agilent Technologies) and verified by 
sequencing using the 3130XL Genetic Analyzer (Life Technologies). Primers 
specific for EWSR1-BEND2 fusion genes are available upon request. To 
identify the EWSR1 fusion partner in the case ITNET_2045, a real-time RT-
PCR translocation panel for detecting specific Ewing sarcomas fusion 
transcripts was applied as described(72). Following identification of the 
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fusion partner, PCR amplicons were subjected to sequencing using the 
3130XL Genetic Analyzer. 
 
5.11 Fluorescent in situ hybridization (FISH) analysis 
EWSR1 rearrangements were assayed on paraffin-embedded tissue 
sections using a commercial split-signal probe (Vysis LSI EWSR1 (22q12) 
Dual Color, Break Apart Rearrangement FISH Probe Kit) that consists of a 
mixture of two FISH DNA probes. One probe (~500 kb) is labelled in 
SpectrumOrange and flanks the 5' side of the EWSR1 gene, extending through 
intron 4, and the second probe (~1100 kb) is labelled in SpectrumGreen and 
flanks the 3' side of the EWSR1 gene, with a 7 kb gap between the two probes. 
With this setting, the assay enables the detection of rearrangements with 
breakpoints spanning introns 7 to 10 of the EWSR1 gene. Hybridization was 
performed according to the manufacturer’s instructions and scoring of tissue 
sections was assessed as described elsewhere(73), counting at least 100 nuclei 
per slide.  
 
5.12 Targeted sequencing 
Recurrently mutated genes identified by whole genome sequencing were 
independently evaluated in a series of 62 PaNETs from the ARC-Net 
Research Centre, University of Verona. Four Ion Ampliseq Custom panel 
(Thermofisher) were designed to target the entire coding regions and flanking 
intron-exon junctions of the following genes: MEN1, DAXX, ATRX, PTEN, 
and TSC2 (panel 1); DEPDC5, TSC1, and SETD2 (panel 2); ARID1A and 
MTOR (panel 3); CHEK2 and MUTYH (panel 4). Twenty nanograms of DNA 
were used per multiplex PCR amplification. The quality of the obtained 
libraries was evaluated by the Agilent 2100 Bioanalyzer on chip 
electrophoresis. Emulsion PCR was performed with the OneTouch system 
(Thermofisher). Sequencing was run on the Ion Torrent Personal Genome 
Machine (PGM, Thermofisher) loaded with 316 or 318 chips. Data analysis, 
including alignment to the hg19 human reference genome and variant calling, 
was done using Torrent Suite Software v4.0 (Thermofisher). Filtered variants 
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were annotated using a custom pipeline based on the Variant Effector 
Predictor (VEP) software. Alignments were visually verified with the 
Integrative Genomics Viewer: IGV v2.3 (Broad Institute).  
 
5.13 Clinical correlations 
The date of diagnosis and the date and cause of death were obtained from 
the Central Cancer Registry and treating clinicians. Median survival was 
estimated using the Kaplan-Meier method and the difference was tested using 
the log-rank Test. P values of less than 0.05 were considered statistically 
significant. Hazard ratio and its 95% confidence interval was estimated using 
Cox proportional hazard regression modelling. The correlation between 
DAXX/ATRX mutational status with other clinico-pathological variables was 
performed using Chi-squared test. Statistical analysis was performed using 
StatView 5.0 Software (Abacus Systems, Berkeley, CA, USA). Disease-
specific survival was used as the primary endpoint. 
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